phrykt

Vor Biopharma Inc. (VOR): who owns it and who trades it

As of Nov 16, 2026, VOR insiders reported 16 open-market sales worth $49.4M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ra Capital Management, L.P. (Director), with $22.1M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Vor Biopharma

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VOR

103 funds and institutions reported VOR shares worth $911M at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is TCG Crossover Management, LLC with 11.6%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

TCG Crossover Management, LLC11.6%
FMR LLC (Fidelity)10.1%
Fcpm III Services B.v.8.4%
BlackRock, Inc.7.1%
Venrock Adviser, LLC6.2%
State Street Corp5.4%
Frazier Life Sciences Management, L.P.5.2%
Ra Capital Management, L.P.4.9%
Vanguard Capital Management LLC4.3%
Caligan Partners LP3.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
TCG Crossover Management, LLC5.67M11.61%$104MNo change
FMR LLC (Fidelity)4.93M10.10%$90.8M+220%
Fcpm III Services B.v.4.12M8.43%$75.8MNo change
BlackRock, Inc.3.47M7.10%$63.8M+336%
Venrock Adviser, LLC3.04M6.23%$56MNo change
State Street Corp2.62M5.36%$48.2M+134%
Frazier Life Sciences Management, L.P.2.54M5.21%$46.8MNo change
Ra Capital Management, L.P.2.40M4.92%$44.2M-56%
Vanguard Capital Management LLC2.08M4.27%$38.4M+45%
Caligan Partners LP1.93M3.94%$35.4MNo change
Paradigm Biocapital Advisors LP1.75M3.58%$32.2MNo change
Great Point Partners LLC1.70M3.48%$31.3M-3%
Nantahala Capital Management, LLC1.69M3.46%$31.1MNew
Geode Capital Management, LLC1.06M2.18%$19.6M+210%
NEXTBio Capital Management LP889,1641.82%$16.4M-11%
ADAR1 Capital Management, LLC680,6261.39%$12.5MNew
Logos Global Management LP650,0001.33%$12M-13%
Rosalind Advisors, Inc.648,6001.33%$11.9M-7%
Nan Fung Trinity (hk) Ltd646,5501.32%$11.9MNew
Braidwell LP573,1041.17%$10.6M+23%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VOR insiders reported $0 of open-market purchases and $49.4M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$49.4M
16 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Jul 16, 2026
Filed Jul 21, 2026

Purchases and sales by month

$49.4M$49.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jul 16, 2026Rajeev M. Shah +310% ownerSale213$19.75$4.2KForm 4
Apr 22, 2026Rajeev M. Shah +3DirectorSale165,150$15.77$2.6MForm 4
Apr 20, 2026Ra Capital Management, L.P. +3DirectorSale171,963$15.77$2.7MForm 4
Apr 17, 2026Ra Capital Management, L.P. +3DirectorSale458,411$16.28$7.5MForm 4
Apr 15, 2026Ra Capital Management, L.P. +3DirectorSale53,644$16.01$859KForm 4
Apr 14, 2026Ra Capital Management, L.P. +3DirectorSale153,735$15.97$2.5MForm 4
Apr 13, 2026Ra Capital Management, L.P. +3DirectorSale530,610$16.15$8.6MForm 4
Apr 10, 2026Rajeev M. Shah +3DirectorSale828$15.75$13KForm 4
Apr 9, 2026Rajeev M. Shah +3DirectorSale135,201$16.59$2.2MForm 4
Apr 8, 2026Rajeev M. Shah +3DirectorSale130,862$16.91$2.2MForm 4
Apr 8, 2026Rajeev M. Shah +3DirectorSale353,242$16.32$5.8MForm 4
Apr 6, 2026Peter Kolchinsky +3DirectorSale44,728$17.31$774KForm 4
Apr 6, 2026Peter Kolchinsky +3DirectorSale6,775$18.50$125KForm 4
Apr 6, 2026Peter Kolchinsky +3DirectorSale537,754$16.51$8.9MForm 4
Apr 2, 2026Peter Kolchinsky +3DirectorSale1,525$19.06$29.1KForm 4
Apr 2, 2026Peter Kolchinsky +3DirectorSale258,475$18.23$4.7MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ra Capital Management, L.P.Director, 10% owner–$22.1MApr 20, 2026
Peter KolchinskyDirector, 10% owner–$14.5MApr 6, 2026
Rajeev M. ShahDirector, 10% owner–$12.8MJul 16, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VOR short interest

High short interest. 12.2% of VOR shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 63%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 7.50M VOR shares were sold short, 12.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 759,510 shares, buying them all back would take about 9.9 trading days (days to cover).

Shares short, % of all shares

12.2%May 15Oct 3016.8%

Days to cover

9.9May 15Oct 3012.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20267.50M12.22%+1%759,5109.9
Oct 15, 20267.45M12.58%-5%830,4559.0
Sep 30, 20267.81M13.21%-1%1.80M4.3
Sep 15, 20267.90M13.36%+3%710,54611.1
Aug 31, 20267.67M12.96%+4%739,51110.4
Aug 14, 20267.35M12.42%+1%747,1129.8
Jul 31, 20267.25M14.85%-1%871,8228.3
Jul 15, 20267.29M14.92%-6%1.67M4.4
Jun 30, 20267.74M15.85%+30%2.06M3.8
Jun 15, 20265.95M12.18%+24%834,0997.1
May 29, 20264.82M9.86%+5%804,5276.0
May 15, 20264.60M9.41%-7%873,8805.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Vor Biopharma company events

Vor Biopharma filed 8 reports on Form 8-K in the last 12 months, 4 of them about an important change (leadership). The latest was on Jul 7, 2026.

  1. Jul 7, 2026LeadershipAndrew Levin, M.D., Ph.D., a member of the Board of Directors of Vor Biopharma Inc., delivered his notice of resignation, effective immediately. Filing
  2. Jun 12, 2026VoteReported shareholder vote results. Filing
  3. Jun 8, 2026AnnouncementShared information with investors. Filing
  4. Mar 27, 2026AgreementVor Biopharma Inc. entered into a Securities Purchase Agreement with entities affiliated with TCGX pursuant to which the Company, in a private placement, agreed to issue and sell to the Investors an aggregate of 5,338,078 shares of the Company’s common stock, at a price per Share of $14.05, for… Filing
  5. Jan 12, 2026ResultsReleased financial results. Filing
  6. Jan 2, 2026LeadershipVor Biopharma Inc. entered into a separation agreement with Dr. Qing Zuraw, the Company’s Chief Development Officer, as a result of Dr. Zuraw’s decision to pursue other opportunities. Filing
  7. Dec 18, 2025LeadershipSarah Reed, a member of the Company’s Board of Directors, delivered her notice of resignation to the Board, effective immediately. Filing
  8. Dec 9, 2025LeadershipThe board of directors of Vor Biopharma Inc. approved a stock option repricing whereby the exercise price of certain outstanding options to purchase shares of the Company’s common stock under the Company’s Amended and Restated 2021 Equity Incentive Plan and the Company’s 2023 Inducement Plan was… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Vor Biopharma financials

Famous investors that hold VOR

4 of the 50 well-known investors we track reported holding VOR in their latest 13F filing. The largest position is Israel Englander's, worth $18.9M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026991,532$18.9M0.0%+132%
Ken Griffin · Citadel AdvisorsQ3 2026497,989$9.5M0.0%+210%
Steve Cohen · Point72 Asset ManagementQ3 2026343,037$6.5M0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202627,468$524K0.0%+40%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named VOR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026TCG Crossover GP II, LLC13G/A4.6%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A9.9%
Nov 16, 2026TCG Crossover GP II, LLC13G/A4.6%
Nov 16, 2026Venrock Healthcare Capital Partners III, L.P.13G/A9.9%
Nov 5, 2026FMR LLC13G/A10.7%
Nov 5, 2026FMR LLC13G/A10.7%

Questions about Vor Biopharma Inc. (VOR) stock

Who owns the most VOR stock?

The largest reported owner of Vor Biopharma Inc. (VOR) is TCG Crossover Management, LLC, with 11.6% of the company. In total, 103 funds and institutions reported holding VOR at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are VOR insiders buying or selling?

In the last 12 months, VOR insiders reported no open-market purchases and 16 sales worth $49.4M. The latest trade was on Jul 16, 2026. See every trade.

What is the short interest in VOR?

As of Oct 30, 2026, 7.50M VOR shares were sold short, 12.2% of the shares outstanding, up 0.8% from the report before. At the average daily volume of 759,510 shares, buying them all back would take about 9.9 trading days (days to cover). See the history.

Which famous investors hold VOR?

4 of the 50 well-known investors we track reported VOR in their latest 13F filing, including Israel Englander, Ken Griffin, Steve Cohen. The largest position is worth $18.9M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.